Pharmaceutical

Orphelia explores avenues for liquid neuroblastoma med after EU CHMP rejection

Europe’s drug regulatory agency has given Kizfizo a negative opinion for the second time, following one from November 2024.

Mar 13, 2025 - 06:00
Orphelia explores avenues for liquid neuroblastoma med after EU CHMP rejection
Europe’s drug regulatory agency has given Kizfizo a negative opinion for the second time, following one from November 2024.
Read the original article

Tags:

Previous Article

Atsena’s ATSN-201 gains FDA fast track status for XLRS treatment

Next Article

Ono earmarks $940m to gain rare blood cancer therapy from Ionis

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT Virtual Event: Putting AI to the Test

STAT Virtual Event: Putting AI to the Test

Sep 20, 2023

Small cell lung cancer: Navigating the global clinical trial landscape

Small cell lung cancer: Navigating the global clinical ...

Dec 17, 2024

Lyndra Therapeutics appoints Adam Sayer new CEO and president

Lyndra Therapeutics appoints Adam Sayer new CEO and pre...

Jan 30, 2025